Tresiba, a daily basal insulin injection, received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally, including the UK and US.

Basal insulin therapy ... icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose, as measured using ...

Two other, long-acting "basal" insulins on the ... plans to reduce the price of Tresiba. "We have vigorously advocated for universal access to affordable insulin products," the senators wrote.

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026.